These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 35354614)

  • 1. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study.
    Amin NB; Darekar A; Anstee QM; Wong VW; Tacke F; Vourvahis M; Lee DS; Charlton M; Alkhouri N; Nakajima A; Yunis C
    BMJ Open; 2022 Mar; 12(3):e056159. PubMed ID: 35354614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Diacylglycerol Acyltransferase 2 Versus Diacylglycerol Acyltransferase 1: Potential Therapeutic Implications of Pharmacology.
    Amin NB; Saxena AR; Somayaji V; Dullea R
    Clin Ther; 2023 Jan; 45(1):55-70. PubMed ID: 36690550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Harrison SA; Bashir MR; Guy CD; Zhou R; Moylan CA; Frias JP; Alkhouri N; Bansal MB; Baum S; Neuschwander-Tetri BA; Taub R; Moussa SE
    Lancet; 2019 Nov; 394(10213):2012-2024. PubMed ID: 31727409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials.
    Harrison SA; Wong VW; Okanoue T; Bzowej N; Vuppalanchi R; Younes Z; Kohli A; Sarin S; Caldwell SH; Alkhouri N; Shiffman ML; Camargo M; Li G; Kersey K; Jia C; Zhu Y; Djedjos CS; Subramanian GM; Myers RP; Gunn N; Sheikh A; Anstee QM; Romero-Gomez M; Trauner M; Goodman Z; Lawitz EJ; Younossi Z; ;
    J Hepatol; 2020 Jul; 73(1):26-39. PubMed ID: 32147362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetyl-CoA carboxylase inhibition disrupts metabolic reprogramming during hepatic stellate cell activation.
    Bates J; Vijayakumar A; Ghoshal S; Marchand B; Yi S; Kornyeyev D; Zagorska A; Hollenback D; Walker K; Liu K; Pendem S; Newstrom D; Brockett R; Mikaelian I; Kusam S; Ramirez R; Lopez D; Li L; Fuchs BC; Breckenridge DG
    J Hepatol; 2020 Oct; 73(4):896-905. PubMed ID: 32376414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
    Younossi ZM; Ratziu V; Loomba R; Rinella M; Anstee QM; Goodman Z; Bedossa P; Geier A; Beckebaum S; Newsome PN; Sheridan D; Sheikh MY; Trotter J; Knapple W; Lawitz E; Abdelmalek MF; Kowdley KV; Montano-Loza AJ; Boursier J; Mathurin P; Bugianesi E; Mazzella G; Olveira A; Cortez-Pinto H; Graupera I; Orr D; Gluud LL; Dufour JF; Shapiro D; Campagna J; Zaru L; MacConell L; Shringarpure R; Harrison S; Sanyal AJ;
    Lancet; 2019 Dec; 394(10215):2184-2196. PubMed ID: 31813633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
    Harrison SA; Frias JP; Neff G; Abrams GA; Lucas KJ; Sanchez W; Gogia S; Sheikh MY; Behling C; Bedossa P; Shao L; Chan D; Fong E; de Temple B; Shringarpure R; Tillman EJ; Rolph T; Cheng A; Yale K;
    Lancet Gastroenterol Hepatol; 2023 Dec; 8(12):1080-1093. PubMed ID: 37802088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
    Loomba R; Kayali Z; Noureddin M; Ruane P; Lawitz EJ; Bennett M; Wang L; Harting E; Tarrant JM; McColgan BJ; Chung C; Ray AS; Subramanian GM; Myers RP; Middleton MS; Lai M; Charlton M; Harrison SA
    Gastroenterology; 2018 Nov; 155(5):1463-1473.e6. PubMed ID: 30059671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH).
    Sivakumar P; Saul M; Robinson D; King LE; Amin NB
    Sci Rep; 2024 Jul; 14(1):17072. PubMed ID: 39048608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis.
    Abdelmalek MF; Charles ED; Sanyal AJ; Harrison SA; Neuschwander-Tetri BA; Goodman Z; Ehman RA; Karsdal M; Nakajima A; Du S; Tirucherai GS; Klinger GH; Mora J; Yamaguchi M; Shevell DE; Loomba R
    Contemp Clin Trials; 2021 May; 104():106335. PubMed ID: 33657443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants.
    Sawant-Basak A; Bergman AJ; Mancuso J; Tripathy S; Gosset JR; Mendes da Costa L; Esler WP; Calle RA
    Clin Transl Sci; 2024 Feb; 17(2):e13687. PubMed ID: 38362827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
    Loomba R; Abdelmalek MF; Armstrong MJ; Jara M; Kjær MS; Krarup N; Lawitz E; Ratziu V; Sanyal AJ; Schattenberg JM; Newsome PN;
    Lancet Gastroenterol Hepatol; 2023 Jun; 8(6):511-522. PubMed ID: 36934740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
    Harrison SA; Abdelmalek MF; Neff G; Gunn N; Guy CD; Alkhouri N; Bashir MR; Freilich B; Kohli A; Khazanchi A; Sheikh MY; Leibowitz M; Rinella ME; Siddiqui MS; Kipnes M; Moussa SE; Younes ZH; Bansal M; Baum SJ; Borg B; Ruane PJ; Thuluvath PJ; Gottwald M; Khan M; Chen C; Melchor-Khan L; Chang W; DePaoli AM; Ling L; Lieu HD
    Lancet Gastroenterol Hepatol; 2022 Jul; 7(7):603-616. PubMed ID: 35325622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
    Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K
    JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study.
    Sven M F; Pierre B; Manal F A; Quentin M A; Elisabetta B; Vlad R; Philippe HM; Bruno S; Jean-Louis J; Pierre B; Jean-Louis A
    Contemp Clin Trials; 2020 Nov; 98():106170. PubMed ID: 33038502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
    Alkhouri N; Herring R; Kabler H; Kayali Z; Hassanein T; Kohli A; Huss RS; Zhu Y; Billin AN; Damgaard LH; Buchholtz K; Kjær MS; Balendran C; Myers RP; Loomba R; Noureddin M
    J Hepatol; 2022 Sep; 77(3):607-618. PubMed ID: 35439567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of Ervogastat (PF-06865571): A Potent and Selective Inhibitor of Diacylglycerol Acyltransferase 2 for the Treatment of Non-alcoholic Steatohepatitis.
    Futatsugi K; Cabral S; Kung DW; Huard K; Lee E; Boehm M; Bauman J; Clark RW; Coffey SB; Crowley C; Dechert-Schmitt AM; Dowling MS; Dullea R; Gosset JR; Kalgutkar AS; Kou K; Li Q; Lian Y; Loria PM; Londregan AT; Niosi M; Orozco C; Pettersen JC; Pfefferkorn JA; Polivkova J; Ross TT; Sharma R; Stock IA; Tesz G; Wisniewska H; Goodwin B; Price DA
    J Med Chem; 2022 Nov; 65(22):15000-15013. PubMed ID: 36322383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
    Ratziu V; Sanyal AJ; Loomba R; Rinella M; Harrison S; Anstee QM; Goodman Z; Bedossa P; MacConell L; Shringarpure R; Shah A; Younossi Z
    Contemp Clin Trials; 2019 Sep; 84():105803. PubMed ID: 31260793
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.